Who are YF vaccine (live)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MMR vaccine, Rotavirus Vaccine, Live, Pentavalent, RotaTeq, Rotarix TM, Attenuated HAV Vaccine, L-A-1 Strain, mOPV2 at 6 and 8 weeks of age.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/yf-vaccine-live.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

YF vaccine (live) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

YF vaccine (live) (YF vaccine (live)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

YF vaccine (live) (YF vaccine (live)) — Sanofi. YF vaccine (live) is a live attenuated yellow fever virus vaccine that stimulates both humoral and cellular immune responses to provide protection against yellow fever infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
YF vaccine (live) TARGET	YF vaccine (live)	Sanofi	phase 3	Live attenuated vaccine
MMR vaccine	MMR vaccine	Sri Edupuganti, MD MPH	marketed	Live attenuated vaccine
Rotavirus Vaccine, Live, Pentavalent	Rotavirus Vaccine, Live, Pentavalent	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine
RotaTeq	RotaTeq	National Institute of Pediatrics, Mexico	marketed	Live attenuated vaccine	Rotavirus VP4 and VP7 surface proteins
Rotarix TM	Rotarix TM	GlaxoSmithKline	marketed	Live attenuated vaccine	Rotavirus (RIX4414 strain)
Attenuated HAV Vaccine, L-A-1 Strain	Attenuated HAV Vaccine, L-A-1 Strain	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Live attenuated vaccine
mOPV2 at 6 and 8 weeks of age	mOPV2 at 6 and 8 weeks of age	Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Poliovirus type 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). YF vaccine (live) — Competitive Intelligence Brief. https://druglandscape.com/ci/yf-vaccine-live. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab